Worth reading
44Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
4.4
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2024年4月1日〜2024年12月31日ConsolidatedJapanese GAAPNet Sales432,545¥ millionYear on year +4.4%Progress 72.1%
Operating profit43,245¥ millionYear on year -2.8%Progress 72.1%
Ordinary income44,795¥ millionYear on year -7.0%Progress 74.7%
Net income attributable to owners of the parent44,042¥ millionYear on year -0.4%Progress 86.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share160円30銭
Financial position at period-end
Total assets861,559¥ million
of which net assets 395,527 ¥ millionEquity ratio 44.0%vs. prior year-end +1.2pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical and Healthcare ¥10,888 million (YoY +3.7%), Smart ¥28,473 million (YoY +13.3%), Safety ¥72,777 million (YoY +0.1%), Materials ¥129,162 million (YoY -2.4%), Engineering Plastics ¥186,828 million (YoY +10.2%), Other (outside reportable segments) ¥4,414 million (YoY +9.6%)
Segment profitMedical and Healthcare ¥365 million (YoY -59.8%), Smart ¥-555 million, Safety ¥3,054 million (YoY +28.1%), Materials ¥19,116 million (YoY -34.4%), Engineering Plastics ¥20,559 million (YoY +69.6%), Other (outside reportable segments) ¥704 million (YoY +232.1%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥600,000 million (YoY +7.5%)
Operating profit¥60,000 million (YoY -8.3%)
Ordinary income¥60,000 million (YoY -3.2%)
Net income¥51,000 million (YoY -7.8%)
Annual Dividend Forecast¥50 → ¥60（+20.0%）
Factors Behind Changes in Business Performance
主要市場の需要回復による販売数量の増加、為替や原材料費などの販売価格転嫁、北米拠点の生産性改善とコストダウン。一方、原材料価格上昇、販売数量増加に伴う経費増加、減価償却費増加、販売調整などが利益を圧迫した。
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNo applicable matters.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on disposal of fixed assets ¥25 million, Gain on sale of investment securities ¥9,717 million, Gain on sale of shares in an affiliated company ¥4,553 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥684 million, Business restructuring loss ¥1,106 million
Depreciation and amortization¥30,201 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End276,942,682 Shares
Treasury Shares at Period-End8,758,266 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年12月31日 |
| Net Sales | ¥432,545 million (YoY +4.4%) |
| Operating profit | ¥43,245 million (YoY -2.8%) |
| Ordinary income | ¥44,795 million (YoY -7.0%) |
| Profit attributable to owners of the parent | ¥44,042 million (YoY -0.4%) |
| Net income per share | 160円30銭 |
| Equity ratio | End of the current fiscal period 44 / End of previous period 42.8 |
| Total assets | ¥861,559 million |
| Net assets | ¥395,527 million |
| Full-year earnings forecast | Net Sales ¥600,000 million (YoY +7.5%) / Operating profit ¥60,000 million (YoY -8.3%) / Ordinary income ¥60,000 million (YoY -3.2%) / Net income ¥51,000 million (YoY -7.8%) |
| Annual Dividend Forecast | ¥50 → ¥60（+20.0%） |
| Segment revenue | Medical and Healthcare ¥10,888 million (YoY +3.7%), Smart ¥28,473 million (YoY +13.3%), Safety ¥72,777 million (YoY +0.1%), Materials ¥129,162 million (YoY -2.4%), Engineering Plastics ¥186,828 million (YoY +10.2%), Other (outside reportable segments) ¥4,414 million (YoY +9.6%) |
| Segment profit | Medical and Healthcare ¥365 million (YoY -59.8%), Smart ¥-555 million, Safety ¥3,054 million (YoY +28.1%), Materials ¥19,116 million (YoY -34.4%), Engineering Plastics ¥20,559 million (YoY +69.6%), Other (outside reportable segments) ¥704 million (YoY +232.1%) |
| Depreciation and amortization | ¥30,201 million |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on disposal of fixed assets ¥25 million, Gain on sale of investment securities ¥9,717 million, Gain on sale of shares in an affiliated company ¥4,553 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥684 million, Business restructuring loss ¥1,106 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 276,942,682 Shares |
| Treasury Shares at Period-End | 8,758,266 Shares |
| Factors Behind Changes in Business Performance | 主要市場の需要回復による販売数量の増加、為替や原材料費などの販売価格転嫁、北米拠点の生産性改善とコストダウン。一方、原材料価格上昇、販売数量増加に伴う経費増加、減価償却費増加、販売調整などが利益を圧迫した。 |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.需要の回復を受けて販売数量が増加したほか、為替や原材料費などの販売価格転嫁、北米拠点の生産性改善、コストダウンを進めた。一方、原材料価格の上昇、販売数量増加に伴う経費増加、減価償却費の増加、販売調整などが利益を押し下げた。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.